Horm Metab Res 2015; 47(09): 668-673
DOI: 10.1055/s-0034-1398492
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

The Response to Gonadotropin-Releasing Hormone and hCG in Men with Prior Chronic Androgen Steroid Abuse and Clinical Hypogonadism

J. N. Flanagan
1   Department of Medicine/Huddinge, Karolinska Institutet and Center for Andrology and Sexual Medicine, Karolinska University Hospital C2:84, Huddinge, Sweden
,
M. Lehtihet
1   Department of Medicine/Huddinge, Karolinska Institutet and Center for Andrology and Sexual Medicine, Karolinska University Hospital C2:84, Huddinge, Sweden
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 21. September 2014

accepted 10. Dezember 2014

Publikationsdatum:
02. Februar 2015 (online)

Abstract

Androgens were initially developed to improve anabolism for therapeutic purposes. An observed side effect is a sustained inability to regain normal gonadal function after long-term use. This study was designed to evaluate the response to a standard GnRH (gonadotropin-releasing hormone) test (100 μg) followed by an hCG (human chorionic gonadotropin) test to evaluate the HPG (hypothalamic-pituitary-gonadal) axis in a subgroup of men with former androgen use (FAU, n=13, mean age 38±8 years) with secondary hypogonadotropic hypogonadism and total serum testosterone levels below 10 nmol/l. For comparison, healthy men (n=8, mean age 41±5 years) and untreated men with idiopathic hypogonadotropic hypogonadism (IHH, n=5, mean age 26±8 years) were included. Five of 13 FAU males had an LH (luteinizing hormone) peak after GnRH over 9.6 U/l, the 5th percentile of normal reference controls. None of the 13 FAU males reached a testosterone response above 16.0 nmol/l after the 72-h hCG stimulation test, the lowest recorded value for healthy male controls. The IHH patients responded to GnRH with an LH peak after 45 min, while the FAU males and healthy controls had an LH peak after 30 min. After hCG stimulation, the IHH patients increased mean testosterone level to 16.8 nmol/l (median 15.0 nmol/l), significantly higher than the FAU males, p<0.05. Current data support that GnRH and 72-h hCG stimulation tests may be valuable clinical tools to evaluate the HPG axis in adults with previous history of complex androgen abuse, and may provide valuable information in clinical management of these men.

 
  • References

  • 1 Handelsman DJ. Androgen misuse and abuse. Best Pract Res Clin Endocrinol Metab 2011; 25: 377-389
  • 2 Basaria S, Wahlstrom JT, Dobs AS. Clinical review 138: Anabolic-androgenic steroid therapy in the treatment of chronic diseases. J Clin Endocrinol Metab 2001; 86: 5108-5117
  • 3 Kanayama G, Hudson JI, Pope Jr HG. Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: a looming public health concern?. Drug Alcohol Depend 2008; 98: 1-12
  • 4 Buckley WE, Yesalis 3rd CE, Friedl KE, Anderson WA, Streit AL, Wright JE. Estimated prevalence of anabolic steroid use among male high school seniors. JAMA 1988; 260: 3441-3445
  • 5 Johnson MD, Jay MS, Shoup B, Rickert VI. Anabolic steroid use by male adolescents. Pediatrics 1989; 83: 92-1924
  • 6 Eklof AC, Thurelius AM, Garle M, Rane A, Sjoqvist F. The anti-doping hot-line, a means to capture the abuse of doping agents in the Swedish society and a new service function in clinical pharmacology. Eur J Clin Pharmacol 2003; 59: 571-577
  • 7 Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope Jr HG. Anabolic-androgenic steroid dependence: an emerging disorder. Addiction 2009; 104: 1966-1978
  • 8 Kanayama G, Hudson JI, Pope Jr HG. Illicit anabolic-androgenic steroid use. Horm Behav 2010; 58: 111-121
  • 9 Ip EJ, Trinh K, Tenerowicz MJ, Pal J, Lindfelt TA, Perry PJ. Characteristics and Behaviors of Older Male Anabolic Steroid Users. J Pharm Pract 2014 Mar 18 [Epub ahead of print]
  • 10 Lundholm L, Frisell T, Lichtenstein P, Langstrom N. Anabolic androgenic steroids and violent offending: Confounding by polysubstance abuse among 10,365 general population men. Addiction 2015; 110: 100-108
  • 11 Alen M, Reinila M, Vihko R. Response of serum hormones to androgen administration in power athletes. Med Sci Sports Exerc 1985; 17: 354-359
  • 12 Merkle T, Landthaler M, Braun-Falco O. Acne conglobata-like exacerbation of acne vulgaris following administration of anabolic steroids and vitamin B complex-containing preparations. Hautarzt 1990; 41: 280-282
  • 13 Palacios A, McClure RD, Campfield A, Swerdloff RS. Effect of testosterone enanthate on testis size. J Urol 1981; 126: 46-48
  • 14 Ruokonen A, Alen M, Bolton N, Vihko R. Response of serum testosterone and its precursor steroids, SHBG and CBG to anabolic steroid and testosterone self-administration in man. J Steroid Biochem 1985; 23: 33-38
  • 15 Garevik N, Strahm E, Garle M, Lundmark J, Stahle L, Ekstrom L, Rane A. Long term perturbation of endocrine parameters and cholesterol metabolism after discontinued abuse of anabolic androgenic steroids. J Steroid Biochem Mol Biol 2011; 127: 295-300
  • 16 Ly LP, Liu PY, Handelsman DJ. Rates of suppression and recovery of human sperm output in testosterone-based hormonal contraceptive regimens. Human Reprod 2005; 20: 1733-1740
  • 17 Urhausen A, Torsten A, Wilfried K. Reversibility of the effects on blood cells, lipids, liver function and hormones in former anabolic-androgenic steroid abusers. J Steroid Biochem Mol Biol 2003; 84: 369-375
  • 18 Arver S, Lehtihet M. Current guidelines for the diagnosis of testosterone deficiency. Front Horm Res 2009; 37: 5-20
  • 19 Rahnema CD, Lipshultz LI, Crosnoe LE, Kovac JR, Kim ED. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril 2014; 101: 1271-1279
  • 20 Donike MGH, Gotzmann A, Kraft M, Mandel F, Nolteernsting E, Eagon PK. Dope analysis. Proceedings, IAF World Symposium on Doping in Sport. Int Athletid Found 1987; 53-80
  • 21 Schanzer W, Donike M. Metabolism of anabolic steroids in man: synthesis and use of reference substances for identification of anabolic steroid metabolites. Anal Chim Acta Amsterdam 1993; 275: 23-48
  • 22 Chung BC, Choo HY, Kim TW, Eom KD, Kwon OS, Suh J, Yang J, Park J. Analysis of anabolic steroids using GC/MS with selected ion monitoring. J Anal Toxicol 1990; 14: 91-95
  • 23 Caminos-Torres R, Ma L, Snyder PJ. Testosterone-induced inhibition of the LH and FSH responses to gonadotropin-releasing hormone occurs slowly. J Clin Endocrinol Metab 1977; 44: 1142-1153
  • 24 Clerico A, Ferdeghini M, Palombo C, Leoncini R, Del Chicca MG, Sardano G, Mariani G. Effect of anabolic treatment on the serum levels of gonadotropins, testosterone, prolactin, thyroid hormones and myoglobin of male athletes under physical training. J Nucl Med Allied Sci 1981; 25: 79-88
  • 25 Dufau ML, Veldhuis JD, Fraioli F, Johnson ML, Beitins IZ. Mode of secretion of bioactive luteinizing hormone in man. J Clin Endocrinol Metab 1983; 57: 993-1000
  • 26 Cailleux-Bounacer A, Reznik Y, Cauliez B, Menard JF, Duparc C, Kuhn JM. Evaluation of endocrine testing of Leydig cell function using extractive and recombinant human chorionic gonadotropin and different doses of recombinant human LH in normal men. Eur J Endocrinol Oslo 2008; 159: 171-178
  • 27 Santen RJ, Paulsen CA. Hypogonadotropic eunuchoidism. II. Gonadal responsiveness to exogenous gonadotropins. J Clin Endocrinol Metab 1973; 36: 55-63
  • 28 Forest MG. How should we perform the human chorionic gonadotrophin (hCG) stimulation test?. Int J Androl 1983; 6: 1-4
  • 29 de Kretser DM, Burger HG, Hudson B, Keogh EJ. The pituitary-testicular response to luteinising hormone releasing hormone administration to normal men. Aust NZ J Med 1975; 5: 227-230
  • 30 Heinrich N, Meyer MR, Furkert J, Sasse A, Beyermann M, Bonigk W, Berger H. Corticotropin-releasing factor (CRF) agonists stimulate testosterone production in mouse leydig cells through CRF receptor-1. Endocrinology 1998; 139: 651-658
  • 31 O’Shaughnessy PJ, Fleming LM, Jackson G, Hochgeschwender U, Reed P, Baker PJ. Adrenocorticotropic hormone directly stimulates testosterone production by the fetal and neonatal mouse testis. Endocrinology 2003; 144: 3279-3284
  • 32 Martikainen H, Alen M, Rahkila P, Vihko R. Testicular responsiveness to human chorionic gonadotrophin during transient hypogonadotrophic hypogonadism induced by androgenic/anabolic steroids in power athletes. J Steroid Biochem 1986; 25: 109-112
  • 33 Mendis-Handagama SM. Luteinizing hormone on Leydig cell structure and function. Histol Histopathol 1997; 12: 869-882
  • 34 Keeney DS, Sprando RL, Robaire B, Zirkin BR, Ewing LL. Reversal of long-term LH deprivation on testosterone secretion and Leydig cell volume, number and proliferation in adult rats. J Endocrinol 1990; 127: 47-58
  • 35 Veldhuis JD, Dufau ML. Actions of estradiol on the pulsatile secretion of bioactive luteinizing hormone in man. Trans Assocait Am Phys 1986; 99: 236-244
  • 36 Veldhuis JD, Dufau ML. Estradiol modulates the pulsatile secretion of biologically active luteinizing hormone in man. J Clin Invest 1987; 80: 631-638
  • 37 Krause W, Holland-Moritz H, Schramm P. Treatment of idiopathic oligozoospermia with tamoxifen – a randomized controlled study. Int J Androl 1992; 15: 14-18